178 related articles for article (PubMed ID: 29139009)
1. LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice.
Sahin K; Tuzcu M; Yabas M; Orhan C; Sahin N; Ozercan IH
Invest New Drugs; 2018 Jun; 36(3):388-395. PubMed ID: 29139009
[TBL] [Abstract][Full Text] [Related]
2. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).
Uckun FM; Dibirdik I; Qazi S; Vassilev A; Ma H; Mao C; Benyumov A; Emami KH
Bioorg Med Chem; 2007 Jan; 15(2):800-14. PubMed ID: 17098432
[TBL] [Abstract][Full Text] [Related]
3. Chemosensitizing anti-cancer activity of LFM-A13, a leflunomide metabolite analog targeting polo-like kinases.
Uckun FM
Cell Cycle; 2007 Dec; 6(24):3021-6. PubMed ID: 18073537
[TBL] [Abstract][Full Text] [Related]
4. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase.
Uckun FM; Zheng Y; Cetkovic-Cvrlje M; Vassilev A; Lisowski E; Waurzyniak B; Chen H; Carpenter R; Chen CL
Clin Cancer Res; 2002 May; 8(5):1224-33. PubMed ID: 12006542
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton's tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors.
Uckun F; Dibirdik I; Sarkissian A; Qazi S
Arzneimittelforschung; 2011; 61(4):252-9. PubMed ID: 21650085
[TBL] [Abstract][Full Text] [Related]
6. In vivo toxicity and antithrombotic profile of the oral formulation of the antileukemic agent, LFM-A13-F.
Tibbles HE; Samuel P; Erbeck D; Mahajan S; Uckun FM
Arzneimittelforschung; 2004; 54(6):330-9. PubMed ID: 15281619
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer.
Tankiewicz-Kwedlo A; Hermanowicz JM; Domaniewski T; Pawlak K; Rusak M; Pryczynicz A; Surazynski A; Kaminski T; Kazberuk A; Pawlak D
Br J Pharmacol; 2018 Mar; 175(5):743-762. PubMed ID: 29160911
[TBL] [Abstract][Full Text] [Related]
8. Preclinical toxicity and pharmacokinetics of the Bruton's tyrosine kinase-targeting anti-leukemic drug candidate, alpha-cyano-beta-hydroxy-beta-methyl-N- (2,5-dibromophenyl) propenamide (LFM-A13).
Uckun FM; Tibbles H; Venkatachalam T; DuMez D; Erbeck D
Arzneimittelforschung; 2007; 57(1):31-46. PubMed ID: 17341007
[TBL] [Abstract][Full Text] [Related]
9. The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity.
van den Akker E; van Dijk TB; Schmidt U; Felida L; Beug H; Löwenberg B; von Lindern M
Biol Chem; 2004 May; 385(5):409-13. PubMed ID: 15196000
[TBL] [Abstract][Full Text] [Related]
10. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide].
Mahajan S; Ghosh S; Sudbeck EA; Zheng Y; Downs S; Hupke M; Uckun FM
J Biol Chem; 1999 Apr; 274(14):9587-99. PubMed ID: 10092645
[TBL] [Abstract][Full Text] [Related]
11. Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001.
Lan R; Lin G; Yin F; Xu J; Zhang X; Wang J; Wang Y; Gong J; Ding YH; Yang Z; Lu F; Zhang H
Lab Invest; 2012 Oct; 92(10):1503-14. PubMed ID: 22890557
[TBL] [Abstract][Full Text] [Related]
12. The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism.
Uckun FM; Vassilev A; Bartell S; Zheng Y; Mahajan S; Tibbles HE
Leuk Lymphoma; 2003 Sep; 44(9):1569-77. PubMed ID: 14565661
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin Intensifies the Proapoptotic Activity of LFM-A13 in Cells and in a Mouse Model of Colorectal Cancer.
Tankiewicz-Kwedlo A; Hermanowicz JM; Pawlak K; Czarnomysy R; Bielawski K; Prokop I; Pawlak D
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29690619
[TBL] [Abstract][Full Text] [Related]
14. Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model.
Cetkovic-Cvrlje M; Uckun FM
Br J Haematol; 2004 Sep; 126(6):821-7. PubMed ID: 15352986
[TBL] [Abstract][Full Text] [Related]
15. The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer.
Rozkiewicz D; Hermanowicz JM; Tankiewicz-Kwedlo A; Sieklucka B; Pawlak K; Czarnomysy R; Bielawski K; Surazynski A; Kalafut J; Przybyszewska A; Koda M; Jakubowska K; Rivero-Muller A; Pawlak D
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1697-1711. PubMed ID: 32912025
[TBL] [Abstract][Full Text] [Related]
16. Polo-like-kinase 1 (PLK1) as a molecular target to overcome SYK-mediated resistance of B-lineage acute lymphoblastic leukaemia cells to oxidative stress.
Uckun FM; Ozer Z; Qazi S; Tuel-Ahlgren L; Mao C
Br J Haematol; 2010 Mar; 148(5):714-25. PubMed ID: 19912216
[TBL] [Abstract][Full Text] [Related]
17. Chemopreventive effect of a novel oleanane triterpenoid in a chemically induced rodent model of breast cancer.
Bishayee A; Mandal A; Thoppil RJ; Darvesh AS; Bhatia D
Int J Cancer; 2013 Sep; 133(5):1054-63. PubMed ID: 23404339
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cells.
Sydor S; Jafoui S; Wingerter L; Swoboda S; Mertens JC; Gerken G; Canbay A; Paul A; Fingas CD
World J Gastroenterol; 2017 Jun; 23(22):4007-4015. PubMed ID: 28652654
[TBL] [Abstract][Full Text] [Related]
19. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
Spänkuch B; Kurunci-Csacsko E; Kaufmann M; Strebhardt K
Oncogene; 2007 Aug; 26(39):5793-807. PubMed ID: 17369857
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of combination of lycopene and genistein on 7,12- dimethyl benz(a)anthracene-induced breast cancer in rats.
Sahin K; Tuzcu M; Sahin N; Akdemir F; Ozercan I; Bayraktar S; Kucuk O
Nutr Cancer; 2011 Nov; 63(8):1279-86. PubMed ID: 21958026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
